HB5191 would direct the Under Secretary of Defense for Research and Engineering to develop and publicly publish guidance within one year on how private entities can demonstrate that biobased products meet Department of Defense requirements, coordinating with the Secretaries of the military departments. The bill also requires the Comptroller General to analyze whether DoD’s requirements unintentionally exclude biobased products and to report within one year with recommendations to reduce any such exclusion.
For definitional clarity, the bill defines a biobased product as one manufactured, produced, or developed through the application of living organisms to alter living or non-living materials.
At a Glance
What It Does
Establishes a deadline and process for DoD to publish guidance showing how private entities can prove biobased products meet DoD requirements; commissions a GAO analysis of potential exclusions in DoD requirements; and defines biobased products for the purpose of the guidance.
Who It Affects
Private biobased product manufacturers seeking DoD contracts, DoD procurement offices, and private testing/certification entities that validate products against DoD criteria.
Why It Matters
Sets a formal pathway to increase transparency and participation of biobased products in the defense supply chain, while ensuring DoD requirements do not unintentionally exclude such products.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill directs the DoD to produce publicly available guidance within a year that explains how private entities can demonstrate that biobased products satisfy DoD requirements. This guidance is to be developed in coordination with the military departments and aims to clarify what evidence is needed to prove capabilities align with DoD needs.
In parallel, the Comptroller General must analyze the DoD requirement-setting process to determine whether biobased products are being unintentionally left out, and must report findings and potential remedies to Congress within a year. The definition of a biobased product centers on products manufactured, produced, or developed using living organisms to alter materials, underscoring a lifecycle and biological basis for the products in question.
Together, these provisions lower practical barriers to entry for biobased solutions in defense markets while fostering accountability around DoD standards.
The Five Things You Need to Know
The bill requires the Under Secretary of Defense for Research and Engineering to publish guidance within one year.
The guidance must be developed in coordination with the Secretaries of the military departments.
The Comptroller General must analyze whether DoD requirements exclude biobased products and report within one year.
The analysis will be shared with congressional defense committees.
“Biobased product” is defined as a product produced or developed via living organisms to alter materials.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Establishing biobased product merit guidance
Not later than one year after enactment, the Under Secretary of Defense for Research and Engineering must develop and publicly release guidance. This guidance, created in coordination with the Secretaries of the military departments, will explain how private entities can demonstrate that biobased products meet DoD requirements. The focus is on providing a clear, practical path for evidence, testing, and documentation that supports defense-use capabilities.
GAO analysis of DoD requirements
The Comptroller General must analyze the DoD process for developing requirements to determine if biobased products are unintentionally excluded. Not later than one year after enactment, the CG shall submit a report to the congressional defense committees detailing findings and, if exclusions exist, recommendations to reduce them. This mechanism introduces an independent check to ensure inclusion of biobased products in defense procurement considerations.
Biobased product defined
The term ‘‘biobased product’’ is defined in this section as a product manufactured, produced, or developed through the application of living organisms to alter living or non-living materials. This definition anchors the guidance and the CG analysis to a concrete biological-product paradigm, guiding evidence standards and testing modalities.
This bill is one of many.
Codify tracks hundreds of bills on Defense across all five countries.
Explore Defense in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Biobased product manufacturers pursuing DoD contracts — clearer pathways and evidence requirements reduce uncertainty in bidding and qualification.
- DoD procurement offices — improved transparency and standardized demonstrations can streamline evaluation and market access for biobased solutions.
- Private testing and certification firms — higher demand for validation services under defined guidelines.
- Defense research and development community — better alignment between product development and procurement criteria.
- Private sector investors in biobased tech — clearer signals about eligibility and standards for defense markets.
Who Bears the Cost
- DoD budget and personnel resources to develop and coordinate the guidance with military departments.
- Private entities that must assemble documentation and evidence to demonstrate DoD compatibility.
- Private testing/certification providers that must validate products against new or clarified criteria.
- GAO and congressional defense committees for oversight and reporting overhead.
Key Issues
The Core Tension
Balancing the push to broaden defense access for biobased products with the need to maintain rigorous, uniform standards and avoid creating new, costly barriers to entry.
The bill creates a new, defense-focused pathway for biobased products by requiring DoD to publish guidance within a year and to assess whether DoD requirements inadvertently exclude such products. In practice, this could accelerate access for biobased solutions into defense programs, but it also imposes new documentation and testing expectations on private firms and expands oversight activity (GAO analysis and a congressional report).
A potential tension is ensuring the guidance remains flexible enough to cover diverse biobased products while remaining specific enough to be actionable for procurement teams. Implementation risks include the administrative burden on DoD to coordinate across military departments and on private entities to generate robust demonstration data, which could affect small players differently from larger incumbents.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.